BACKGROUND: The few controlled studies of methylphenidate (MPH) in adults with attention deficit/hyperactivity disorder (ADHD) have reported equivocal results. A previous, pilot study by our group suggested that these results were due to inadequate dosing. METHOD: We conducted a randomized, 6-week, placebo-controlled, parallel study of MPH in 146 adult patients with DSM-IV ADHD using standardized instruments for diagnosis, separate assessments of ADHD, depressive and anxiety symptoms, and a robust average oral daily dose of 1.1 mg/kg/day. RESULTS: We found a marked therapeutic response for the MPH treatment of ADHD symptoms that exceeded the placebo response (76% vs. 19%). Treatment was safe and well tolerated. Response to MPH was independent of socioeconomic status, gender, and lifetime history of psychiatric comorbidity. CONCLUSIONS: These results confirm that robust doses of MPH are effective in the treatment of adult ADHD.
RCT Entities:
BACKGROUND: The few controlled studies of methylphenidate (MPH) in adults with attention deficit/hyperactivity disorder (ADHD) have reported equivocal results. A previous, pilot study by our group suggested that these results were due to inadequate dosing. METHOD: We conducted a randomized, 6-week, placebo-controlled, parallel study of MPH in 146 adult patients with DSM-IV ADHD using standardized instruments for diagnosis, separate assessments of ADHD, depressive and anxiety symptoms, and a robust average oral daily dose of 1.1 mg/kg/day. RESULTS: We found a marked therapeutic response for the MPH treatment of ADHD symptoms that exceeded the placebo response (76% vs. 19%). Treatment was safe and well tolerated. Response to MPH was independent of socioeconomic status, gender, and lifetime history of psychiatric comorbidity. CONCLUSIONS: These results confirm that robust doses of MPH are effective in the treatment of adult ADHD.
Authors: Mary V Solanto; David J Marks; Jeanette Wasserstein; Katherine Mitchell; Howard Abikoff; Jose Ma J Alvir; Michele D Kofman Journal: Am J Psychiatry Date: 2010-03-15 Impact factor: 18.112
Authors: Daniel K Campbell-Meiklejohn; Arndis Simonsen; Mads Jensen; Victoria Wohlert; Trine Gjerløff; Jørgen Scheel-Kruger; Arne Møller; Chris D Frith; Andreas Roepstorff Journal: Neuropsychopharmacology Date: 2012-02-08 Impact factor: 7.853
Authors: Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: J Pediatr Psychol Date: 2009-05-22